Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open Label Study of Intravenous Ascorbic Acid in Combination With Gemcitabine and Erlotinib in the Treatment of Metastatic Pancreatic Cancer

NCT01555489 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.

NCT NCT01555489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01555489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open Label Study of Intravenous Ascorbic Acid in Combination With Gemcitabine and Erlotinib in the Treatment of Metastatic Pancreatic Cancer
Lead sponsor
Thomas Jefferson University
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2011
Completion date
January 31, 2016
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iv pancreatic cancer